文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

前列腺及盆腔SABR联合或不联合局灶推量:多中心II期前瞻性临床试验结果

Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial.
PubMed 文献 · Clin Transl Radiat Oncol · 2026-08-11

这项多中心II期研究评估了前列腺癌患者接受5次分割盆腔SABR(同步整合 elective 淋巴结照射25Gy、前列腺40Gy,可选局灶推量至50Gy)的安全性和可行性。76例患者中急性≥2级胃肠道和泌尿生殖系统不良事件分别为4.1%和18%,5年累积生化失败率为10.5%,无3级以上胃肠道/泌尿生殖系统不良事件。结论认为该方案在多中心环境下安全可行,PSA动力学和生化控制令人鼓舞。

要点

  • 5次分割盆腔SABR联合可选前列腺局灶推量在多中心环境下安全可行。
  • 急性≥2级胃肠道和泌尿生殖系统不良事件分别为4.1%和18%。
  • 5年累积生化失败率10.5%,中位PSA最低点0.2 ng/mL。

核心结论

  • 对不良风险前列腺癌行5次分割前列腺及盆腔SABR联合或不联合局灶推量,在多中心环境下安全可行。
  • 显著不良事件少,PSA动力学和生化控制令人鼓舞,结果正在随机试验中验证。

研究设计与样本

  • 多中心、II期前瞻性临床试验,纳入不良中危或高危前列腺癌患者。
  • 所有患者接受每周5次分割SABR:盆腔 elective 淋巴结照射25Gy、前列腺同步40Gy,可选前列腺局灶推量至50Gy,所有患者接受ADT。
  • 共4家医院入组76例患者,中位随访62.8个月,主要终点为急性胃肠道和泌尿生殖系统不良事件。

主要发现

  • 63%的患者为高危前列腺癌,41%的患者接受局灶推量。
  • 急性≥2级胃肠道和泌尿生殖系统不良事件发生率分别为4.1%和18%。
  • 5年时2.9%和4.3%的患者分别有2级胃肠道和泌尿生殖系统不良事件,末次随访时未观察到3级以上胃肠道/泌尿生殖系统不良事件。
  • 5年累积生化失败率为10.5%,中位PSA最低点为0.2 ng/mL。
  • 84%的患者睾酮水平恢复,中位恢复时间14.3个月;EPIC泌尿、肠道和性功能领域生活质量大幅变化(SD*2)的患者比例分别为2.9%、5.9%和4.6%。

临床怎么用

  • 该5次分割SABR方案(盆腔25Gy、前列腺40Gy、可选局灶推量至50Gy)联合ADT可作为不良风险前列腺癌的多中心可行治疗选择。
  • 治疗决策时可参考其较低的急性及晚期≥2级胃肠道/泌尿生殖系统毒性及良好的5年生化控制。

局限性

  • 为单臂II期研究,无对照组,结果需随机试验验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Given the complexity of SABR to the pelvis in prostate cancer (PCa), it was important to establish the safety and feasibility in a multicentric setting. We report the outcomes of a multicenter, phase II study of SABR with elective nodal irradiation (ENI) and an optional prostate focal boost. METHODS: Patients had unfavorable-intermediate or high-risk PCa. All patients received 5 fractions SABR weekly delivering 25Gy ENI and 40Gy to prostate simultaneously, with an optional 50Gy focal prostate boost. All patients had ADT. Primary endpoint was acute GI and GU adverse events (AE). RESULTS: 76 patients were accrued at 4 hospitals with a median follow-up of 62.8 months. 63% of patients had high-risk PCa. 41% of patients had a focal boost. Acute grade ≥ 2 GI and GU AE was 4.1% and 18%. At 5 years, 2.9% and 4.3% of patients had grade 2 GI and GU AE, and no grade 3+ GI/GU AE was observed at the last follow-up. 5-year cumulative biochemical failure was 10.5%. The median PSA nadir was 0.2 ng/mL. 84% of patients recovered their testosterone level, with a median time of 14.3 months. 2.9%, 5.9% and 4.6% of patients had a large change in QOL (SD*2) in the EPIC urinary, bowel, and sexual domains. CONCLUSIONS: 5-fraction SABR to prostate and pelvis for unfavorable-risk PCa was safe and feasible in a multicentric setting with or without a focal boost. There were few significant AE, encouraging PSA kinetics and biochemical control. The results are currently being validated in randomized trials.

来源:Clin Transl Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Alayed Y, Gopaul D, Mendez LC, et al. Prostate and pelvic SABR with or without a focal boost: results from a multicenter phase II prospective clinical trial. Clin Transl Radiat Oncol. 2026. PMID: 42750816. doi:10.1016/j.ctro.2026.101256

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。